BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36087918)

  • 1. Systemic anti-cancer therapy patterns in advanced non-small cell lung cancer in Europe.
    Hofmarcher T; Lindgren P; Wilking N
    J Cancer Policy; 2022 Dec; 34():100362. PubMed ID: 36087918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative.
    Soares M; Antunes L; Redondo P; Borges M; Hermans R; Patel D; Grimson F; Munro R; Chaib C; Lacoin L; Daumont M; Penrod JR; O'Donnell JC; Bento MJ; Rocha Gonçalves F
    BMC Pulm Med; 2020 Sep; 20(1):240. PubMed ID: 32912174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-small cell lung cancer chemotherapy treatment outcomes and ethnicity: a twenty-year single-centre patterns of care study.
    Nguyen H; Keenan R; Kennedy I; Lao C; Lawrenson R
    N Z Med J; 2023 Nov; 136(1585):24-34. PubMed ID: 37956355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in the prescription of systemic anticancer therapy and mortality among patients with advanced non-small cell lung cancer: a real-world retrospective observational cohort study from the I-O optimise initiative.
    Snee M; Cheeseman S; Thompson M; Riaz M; Sopwith W; Lacoin L; Chaib C; Manley Daumont M; Penrod JR; O'Donnell JC; Hall G
    BMJ Open; 2021 May; 11(5):e043442. PubMed ID: 33941627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with early mortality in non-small cell lung cancer patients following systemic anti-cancer therapy: A 10 year population-based study.
    Gibson AJW; Li H; D'Silva A; Elegbede AA; Tudor RA; Otsuka S; Bebb DG; Cheung WY
    Lung Cancer; 2019 Aug; 134():141-146. PubMed ID: 31319972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significant changes in advanced lung cancer survival during the past decade in Hungary: impact of modern immunotherapy and the COVID-19 pandemic.
    Kiss Z; Gálffy G; Müller V; Moldvay J; Sárosi V; Pápai-Székely Z; Csada E; Kerpel-Fronius A; Király Z; Szász Z; Hódi G; Polányi Z; Kovács K; Karamousouli E; Knollmajer K; Szabó TG; Berta A; Vokó Z; Rokszin G; Abonyi-Tóth Z; Barcza Z; Tamási L; Bogos K
    Front Oncol; 2023; 13():1207295. PubMed ID: 37860193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis.
    Hardtstock F; Myers D; Li T; Cizova D; Maywald U; Wilke T; Griesinger F
    BMC Cancer; 2020 Mar; 20(1):260. PubMed ID: 32228520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensity of end-of-life health care and mortality after systemic anti-cancer treatment in patients with advanced lung cancer.
    Oselin K; Pisarev H; Ilau K; Kiivet RA
    BMC Cancer; 2021 Mar; 21(1):274. PubMed ID: 33722202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of third-generation chemotherapy on the survival of patients with advanced non-small cell lung cancer in Norway: a national study.
    von Plessen C; Strand TE; Wentzel-Larsen T; Omenaas E; Wilking N; Sundstrøm S; Sörenson S
    Thorax; 2008 Oct; 63(10):866-71. PubMed ID: 18390631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality within 30 days following systemic anti-cancer therapy, a review of all cases over a 4 year period in a tertiary cancer centre.
    Khoja L; McGurk A; O'Hara C; Chow S; Hasan J
    Eur J Cancer; 2015 Jan; 51(2):233-40. PubMed ID: 25500146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs and Cost Drivers Associated with Non-Small-Cell Lung Cancer Patients Who Received Two or More Lines of Therapy in Europe.
    Verleger K; Penrod JR; Manley Daumont M; Solem C; Luo L; Macahilig C; Hertel N
    Clinicoecon Outcomes Res; 2020; 12():23-33. PubMed ID: 32021337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is Systemic Anticancer Therapy Associated With Higher Rates of Malignant Pleural Effusion Control in People With Pharmacologically Sensitive Tumors?: A Retrospective Analysis of Prospectively Collected Data.
    Holling N; Patole S; Medford ARL; Maskell NA; Bibby AC
    Chest; 2021 Nov; 160(5):1915-1924. PubMed ID: 34023321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eastern Europe: pronatalist policies and private behavior.
    David HP
    Popul Bull; 1982 Feb; 36(6):1-49. PubMed ID: 12338315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Patient Characteristics, Treatment Patterns, and Mutation Testing Patterns Among US Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations.
    He J; Pericone CD; Vanderpoel J
    Adv Ther; 2022 Jul; 39(7):3347-3360. PubMed ID: 35674970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-Throughput Antigen Microarray Identifies Longitudinal Prognostic Autoantibody for Chemoimmunotherapy in Advanced Non-Small Cell Lung Cancer.
    Dai L; Tan Q; Li L; Lou N; Zheng C; Yang J; Huang L; Wang S; Luo R; Fan G; Xie T; Yao J; Zhang Z; Tang L; Shi Y; Han X
    Mol Cell Proteomics; 2024 May; 23(5):100749. PubMed ID: 38513890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation.
    Prelaj A; Lo Russo G; Proto C; Signorelli D; Ferrara R; Galli G; De Toma A; Randon G; Pagani F; Trevisan B; Ganzinelli M; Zilembo N; Montrone M; Longo V; Pesola F; Pizzutilo P; Del Bene G; Varesano N; Galetta D; Torri V; Garassino MC; Di Maio M; Catino A
    Clin Lung Cancer; 2020 Sep; 21(5):e337-e348. PubMed ID: 32291212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of 30-Day Mortality Following Systemic Anti-Cancer Treatment as a Quality Indicator in Advanced Lung Cancer.
    Roberts HN; Solomon B; Harden S; Lingaratnam S; Alexander M
    Clin Lung Cancer; 2024 Apr; ():. PubMed ID: 38772809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Better together? costs of first-line chemoimmunotherapy for advanced non-small cell lung cancer.
    Kish J; Liassou D; Hartman J; Lubinga SJ; Chopra D; Feinberg B
    Am J Manag Care; 2023 May; 29(5):e129-e135. PubMed ID: 37229786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Information on worldwide abortion legislation].
    Kahn-nathan J
    Fertil Orthog; 1972 Jan; 4(1):17-21. PubMed ID: 12256682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.